FILTER
FILTERED ARTICLE RESULTS
A West-Meets-East Of The Pharma Industry
January 31, 2020
Portrait of the Turkey Pharmaceuticals industry.
The 2020s: India’s decade?
November 19, 2019
As 2020 approaches, GBR takes a look at how far India has come to achieving its Pharma Vision 2020
U.S. Pharmaceuticals: The East Coast
July 25, 2019
From New England to the Mid-Atlantic, a rising tide lifts all boats across the biopharma value chain.
Financing Early Stage Drug Candidates Through Their Future Royalties: A New Form of Capital
May 23, 2019
Expert Opinion Article contributed by Jim Neal, CEO of the biotech enterprise XOMA.
Serialization Regulations Put Packaging Into the Limelight
April 24, 2019
Changing serialization requirements represent an opportunity for packaging companies that are looking to add value for their clients.
Breaking Down Drug Pricing
April 01, 2019
The U.S. biopharmaceuticals industry continues to grapple with the perennial issue of drug pricing.
Standing Out in the Biotech Crowd: The VC Investment Climate
February 06, 2019
With biotechs now accounting for 70% of clinical trials in the United States, the VC private investment climate is heating up.
The Indispensable Partner: Contract Services
October 31, 2018
Large Pharma companies often turn to CMOs and CDMOs for specialized expertise, while Biotech startups rely upon their labs and hardware, resulting in a rapidly expanding and increasingly global business.
From Volume to Value: A Shift in Innovation Focus in the U.S.
August 30, 2018
Precision medicine and the understanding that every patient is different are driving drug discovery.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
Latam North and Caribbean Mining 2025 - Digital Interactive
A convergence of high-commodity prices and low valuations, on the back of a structural deficit in exploration and discoveries, has set the perfect scene for increased M&A. The leverage is particularly high for acquisitions in Latam North and the Caribbean, where stocks do not command the high premiums of tier-one jurisdictions. But M&A is only a quick fix to the global resource replenishment crisis.
A convergence of high-commodity prices and low valuations, on the back of a structural deficit in exploration and discoveries, has set the perfect scene for increased M&A. The leverage is particularly high for acquisitions in Latam North and the Caribbean, where stocks do not command the high premiums of tier-one jurisdictions. But M&A is only a quick fix to the global resource replenishment crisis.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
